Living diagnostics

Osteomyelitis – infection of the bone, and septic arthritis – joint infection, are serious medical conditions that can significantly impact a patient's quality of life. Bone and joint infections, often referred to as (BJIs), are notoriously difficult to treat and successful therapy requires organism-specific antimicrobial therapy at high doses for a prolonged duration.1 Diagnostics can support the identification and management of BJIs, while helping slow the progression of antimicrobial resistance (AMR).

At bioMérieux, we proudly operate at the forefront of diagnostics, supporting customers across the food and drinks industry to help protect consumers and strive for the very highest standards of safety and quality. As we enter 2025, we reflect on the trends we can expect to see in this important sector this year.

A world-renowned pioneer in the field of molecular biotechnology and currently Emeritus Professor at the Department of Biological Sciences, National University of Singapore (NUS), Professor Jeak Ling Ding’s research focuses on innate immunity in host-pathogen interaction, antimicrobial defense and anticancer immunomodulation. Her work has resulted in around 300 scientific publications and patents, along with a host of awards and honors, including most recently her induction into the Singapore Women’s Hall of Fame. We spoke with Professor Ding to learn more about her career defining breakthrough to genetically engineer recombinant Factor C, and the importance of creating a sustainable and ethical alternative to replace traditional methods of endotoxin testing.

Antimicrobial Resistance (AMR) is a term that is not widely recognised by many people globally. What’s even more concerning is that those who are most affected by AMR—patients and their families—are often the ones who lack that awareness and rely on understanding its consequences.